Human-tissue-related inventions: ownership and intellectual property rights in international collaborative research in developing countries.
There are complex unresolved ethical, legal and social issues related to the use of human tissues obtained in the course of research or diagnostic procedures and retained for further use in research. The question of intellectual property rights over commercially viable products or procedures that are derived from these samples and the suitability or otherwise of participants relinquishing their rights to the samples needs urgent attention. The complexity of these matters lies in the fact that the relationship between intellectual property rights and ownership or rights pertaining to the samples on which the intellectual property right is based may either be overlooked or taken for granted. What equally makes the matter complex is that samples may be obtained from participants in developing countries and exported to developed countries for analysis and research. It is important for research ethics committees to tread carefully when reviewing research protocols that raise such issues for purposes of ensuring that appropriate benefit sharing agreements, particularly with developing countries, are in place. This paper attempts to analyse the key questions related to ownership and intellectual property rights in commercially viable products derived from human tissue samples. Patent law is used as a point of reference as opposed to other forms of intellectual property rights such as industrial designs because it is the right that most inventors apply for in respect of human tissue-related inventions. The key questions are formulated following a systematic analysis of peer reviewed journal articles that have reported original investigations into relevant issues in this field. Most of the cases and reported studies that are referred to in this paper do not directly deal with HIV/AIDS research but the underlying principles are helpful in HIV/AIDS research as well. Pertinent questions, which members of ethics review committees should focus on in this regard are discussed and suggestions on appropriate approaches to the issues are proposed in the form of specific questions that an ethics review committee should consider. Specific recommendations regarding areas for further research and action are equally proposed.
Andanda
P A
PA
University of Witwatersrand, Private Bag 3, WITS 2050, Johannesburg, South Africa. Pamela.Andanda@wits.ac.za
D016915:AIDS Vaccines; D003906:Developing Countries; D032984:Ethics, Research; D005062:European Union; D005544:Forecasting; D006801:Humans; D007258:Informed Consent / Q000941:ethics / Q000331:legislation & jurisprudence; D018973:Intellectual Property; D010067:Ownership / Q000941:ethics* / Q000331:legislation & jurisprudence* / Q000639:trends; D011050:Policy Making; D009927:Tissue and Organ Procurement / Q000941:ethics* / Q000331:legislation & jurisprudence* / Q000639:trends; D014481:United States
D016915:AIDS Vaccines